J&J Talc Litigation After the Bankruptcy Collapse: Trials and Mediation Resume
With J&J's third attempt to resolve talc claims in bankruptcy rejected, the largest active MDL in the federal system — roughly 68,000 cases — is back in court. As of June 2026, the company said it was not currently pursuing a global settlement, even as a court-appointed mediator worked in the background.
Update, July 28, 2026: this article has been superseded
On July 27, 2026, Johnson & Johnson announced a proposed $5.5 billion settlement of approximately 76,000 ovarian cancer talc claims. The article below is a June 2026 snapshot and was accurate as of that date. Its statement that J&J was not pursuing a global settlement reflects the company's position in June 2026 and is no longer current.
Read the July 2026 settlement report Key Takeaways
- J&J's third bankruptcy attempt — filed through subsidiary Red River Talc (a ~$8–9B plan) — was rejected on March 31, 2025, so all MDL claims then proceeded in court
- As of June 2026, J&J had publicly stated it was not currently pursuing a global settlement and intended to defend the cases. This position changed on July 27, 2026
- A court-appointed mediator (Fouad Kurdi) has convened settlement sessions under Judge Shipp's order; Carter Judkins was selected as the first federal bellwether in June 2025, and no trial date has been publicly confirmed
- Recent context: a March 2026 federal jury returned a $50M mesothelioma verdict; a Los Angeles court vacated $950M in punitive damages while leaving a $16M compensatory award
- This is the largest active MDL in the federal system at roughly 68,000 pending cases
The bankruptcy route is closed
After two earlier "Texas two-step" filings were dismissed, J&J's third attempt — through its subsidiary Red River Talc, proposing roughly $8–9 billion — was rejected by the bankruptcy court on March 31, 2025. J&J did not appeal and withdrew the settlement offer. As a result, the talc claims proceeded in the MDL before Judge Michael Shipp and in state courts, rather than through Chapter 11.
Mediation continues, but no global deal (as of June 2026)
A court-appointed mediator (Fouad Kurdi) has convened settlement sessions under an order requiring representatives with full authority on both sides. As of June 2026, when this article was published, J&J had continued to say it was not currently pursuing a global settlement. Carter Judkins was selected as the first federal bellwether in June 2025; no trial date has been publicly confirmed. This is general litigation reporting; figures and case names are attributed to the sources below and remain subject to docket confirmation.
J&J's position changed the following month. On July 27, 2026 the company announced a proposed $5.5 billion resolution of roughly 76,000 ovarian talc claims. See our July 2026 settlement report.
Full J&J Talc MDL background & eligibility
For the complete overview — the science, verdict history, and how cases proceed — visit our case hub.
Sources
- • Reporting on the 2025 dismissal of the Red River Talc Chapter 11 plan (Reuters/AP/Bloomberg).
- • Drugwatch talc settlement tracker, as of June 2026: "J&J is not currently pursuing a global talcum powder ovarian cancer settlement." (Superseded by J&J's July 27, 2026 announcement.)
- • D.N.J. MDL-2738 docket and pretrial orders; JPML statistics.
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.